CD38-targeted PET/CT for detecting Multiple Myeloma lesions compared with FDG PET/CT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers compare a CD38-targeted PET/CT imaging method to the usual FDG PET/CT in adults with multiple myeloma or suspected recurrence. The study uses concurrent imaging to quantify tumor uptake and count lesions, then analyzes diagnostic accuracy against standard imaging. It is noninvasive and focuses on imaging performance rather than therapy. Enrollment includes adults requiring both imaging modalities, with analysis based on SUVmax and lesion counts.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
* Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Where it's running

• The First Affliated Hospital of Guilin Medical University
  Guilin, Guangxi, China Recruiting

Study contacts

• Study coordinator: Xingyu Mu, M.D.
• Email: muxingyu1992@hotmail.com
• Phone: 86 13347631119

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• Geriatric assessment before CAR‑T or bispecific antibody therapy to predict side effects and outcomes in older adults

  This study will test whether a brief geriatric assessment done before CAR‑T or bispecific antibody treatment can help predict side effects and outcomes for people aged 65 and older with aggressive lymphoma or multiple myeloma.

  Recruiting at 2 sites University of Zurich · Bern and 1 other locations · NCT07309497

• AI-assisted health education for people with blood cancers

  This project tests whether an AI chatbot can improve awareness of clinical trials and willingness to join among adults with blood cancers.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07305337

• Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers

  This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.

  Recruiting Medical University of Gdansk · Gdansk, Pomeranian Voivodeship · NCT07270263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.